Prophylactic Treatment of Migraine
- PMID: 28360581
- PMCID: PMC5353075
- DOI: 10.4274/npa.y7199
Prophylactic Treatment of Migraine
Abstract
Migraine is a common chronic neurological disease characterized by episodic attacks of headache and associated symptoms. The pharmacological treatment of migraine may be acute or prophylactic, and patients with frequent, severe headaches often require both approaches. Prophylactic treatment is used to reduce the frequency, duration, or severity of attacks, to enhance the benefits of acute treatments, and to improve patient's ability to function normally. Prophylactic treatment may also prevent progression from episodic migraine to chronic migraine and may result in reductions in health-care cost. The currently available pharmacological options for migraine prophylaxis include a wide array of medications. The major medication groups for prophylactic treatment include β-blockers, anticonvulsant, drugs such as topiramate and valproate, antidepressant drugs, such as amitriptyline and selective serotonin and selective serotonin-norepinephrine reuptake inhibitors (SNRIs), calcium channel antagonists and neurotoxins. The agent for prophylactic treatment should be chosen based on the efficacy and side-effect profile of the drug, and the patient's coexistent and comorbid conditions.
Migren epizodik başağrısı atakları ve eşlik eden semptomlarla karakterize sık rastlanılan kronik nörolojik bir hastalıktır. Migrenin farmakolojik tedavisi akut veya profilaktik tedavileri içerir, sık ve şiddetli başağrısı atakları olan hastalar her iki tedaviye de gereksinim duyarlar. Profilaktik tedavi başlıca atak sıklığı, süresi ve şiddetini azaltmak, akut tedavi yararlanımını artırmak ve hastanın fonksiyonel durumunu iyileştirmek amacıyla kullanılır. Profilaktik tedavi ayrıca epizodik migrenin kronik migrene dönüşümünü önleyebilir ve sağlık harcamalarında azalma sağlayabilir. Migren profilaksisinde kullanımda olan farmakolojik ilaç seçenekleri oldukça geniştir. Profilaktik tedavide kullanılan başlıca gruplar β-blokerler, topiramat ve valproat gibi antikonvülzan ilaçlar, amitriptilin ve selektif serotonin ve selektif serotonin-norepinefrin gerialım inhibitorleri (SNRI’lar) gibi antidepresanlar, kalsiyum kanal antagonistleri ve nörotoksinlerdir. Profilaktik tedavide kullanılacak ilaç, etkinlik ve yan etki profiline göre seçilmeli, hastanın eşlik eden ve komorbid hastalıkları da göz önünde bulundurulmalıdır.
Keywords: Migraine; prophylactic treatment.
Conflict of interest statement
Conflict of interest: The authors reported no conflict of interest related to this article Çıkar çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması bildirmemişlerdir.
Similar articles
-
Preventive treatment of migraine.Rev Neurol Dis. 2005 Fall;2(4):167-75. Rev Neurol Dis. 2005. PMID: 16622394 Review.
-
The acute and preventative treatment of episodic migraine.Ann Indian Acad Neurol. 2012 Aug;15(Suppl 1):S33-9. doi: 10.4103/0972-2327.99998. Ann Indian Acad Neurol. 2012. PMID: 23024562 Free PMC article.
-
[Prophylactic treatments of migraine].Rev Neurol (Paris). 2000;156 Suppl 4:4S79-86. Rev Neurol (Paris). 2000. PMID: 11139754 Review. French.
-
Preventive treatment of migraine: an overview.Cephalalgia. 1997 Apr;17(2):67-72. doi: 10.1046/j.1468-2982.1997.1702067.x. Cephalalgia. 1997. PMID: 9137840 Review.
-
Practical considerations for the treatment of elderly patients with migraine.Drugs Aging. 2006;23(6):461-89. doi: 10.2165/00002512-200623060-00003. Drugs Aging. 2006. PMID: 16872231 Review.
Cited by
-
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective.Pharmacoeconomics. 2024 Jul;42(7):811-822. doi: 10.1007/s40273-024-01380-0. Epub 2024 May 21. Pharmacoeconomics. 2024. PMID: 38771521 Free PMC article.
References
-
- Headache Classification Committee. The international classification of headache disorders, 2nd edition. Cephalalgia. 2004;24:1–160. - PubMed
-
- Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF The American Migraine Prevalence and Prevention Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–349. - PubMed
-
- Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009;27:429–443. - PubMed
-
- Silberstein SD, Winner PK, Chmiel JJ. Migrain preventive medication reduces resource utilization. Headache. 2003;43:171–178. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources